EUCTR2004-001842-34-IT进行中（未招募）不适用
A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma - doxil/caelyx plus velcade versus velcade alone in relapse multiple myelomaRecurred or relapsed multiple myelomaEUCTR2004-001842-34-GBJanssen Cilag International NV646
进行中（未招募）
不适用
A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma - doxil/caelyx plus velcade versus velcade alone in relapse multiple myelomaRecurred or relapsed multiple myelomaEUCTR2004-001842-34-ATJohnson & Johnson Pharmaceutical Research and Development630
进行中（未招募）
不适用
A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma - doxil/caelyx plus velcade versus velcade alone in relapse multiple myelomaEUCTR2004-001842-34-CZJJANSSEN-CILAG; JOHNSON & JOHNSON spol. s r.o.630
进行中（未招募）
1 期
A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma - doxil/caelyx plus velcade versus velcade alone in relapse multiple myelomaRecurred or relapsed multiple myelomaEUCTR2004-001842-34-ESJohnson&Johnson Pharmaceutical Research and Development, Division de Janssen-Cilag646
已完成
3 期
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple MyelomaMultiple MyelomaNCT00103506Janssen Research & Development, LLC646